EICHORCondition: Hidradenitis Suppurativa · Sponsor: Eli Lilly and Company
This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Medical Dermatology Specialists | Phoenix, Arizona, United States | — |
| Saguaro Dermatology Associates, LLC - Probity - PPDS | Phoenix, Arizona, United States | — |
| Arkansas Research Trials, LLC | North Little Rock, Arkansas, United States | — |
| Northwest Arkansas Clinical Trials Center | Rogers, Arkansas, United States | — |
| First OC Dermatology Research Inc | Fountain Valley, California, United States | — |
| Center For Dermatology Clinical Research, Inc. | Fremont, California, United States | — |
| Dermatology Research Associates | Los Angeles, California, United States | — |
| Dermatology Institute and Skin Care Center | Santa Monica, California, United States | — |
| University of Connecticut | Farmington, Connecticut, United States | — |
| Direct Helpers Research Center | Hialeah, Florida, United States | — |
| University of Miami | Miami, Florida, United States | — |
| Skin Research of South Florida | Miami, Florida, United States | — |
+ 62 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06046729